5-HT2A and muscarinic receptors in schizophrenia: A postmortem study

Neuroscience Letters

Volumn 379, Issue 3, 2005, Pages 164-168

  Matsumoto, Izuru ^a   Inoue, Yuki ^b   Iwazaki, Takeshi ^a   Pavey, Geoff ^c   Dean, Brian ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

5 HT2A receptors; Muscarinic receptors; Schizophrenia; 3H Ketanserin; 3H Pirenzepine

Indexed keywords

KETANSERIN; MUSCARINIC M1 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR; PIRENZEPINE; SEROTONIN 2A RECEPTOR; TRITIUM; MUSCARINIC RECEPTOR BLOCKING AGENT; SEROTONIN ANTAGONIST;

ARTICLE; AUTOPSY; AUTORADIOGRAPHY; CAUDATE NUCLEUS; CONTROLLED STUDY; DENSITY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PUTAMEN; RECEPTOR BINDING; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; AGED; BRAIN; CADAVER; CASE CONTROL STUDY; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROTEIN BINDING;

AGED; AGED, 80 AND OVER; AUTORADIOGRAPHY; BRAIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; KETANSERIN; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PIRENZEPINE; POSTMORTEM CHANGES; PROTEIN BINDING; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, MUSCARINIC; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; TRITIUM;

EID: 17444423355     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2004.12.059     Document Type: Article

References (31)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders third ed., revised 1987 American Psychiatric Press Washington, DC
2. R.C. Arora, and Meltzer HY Serotonin2 (5HT-2) receptor binding in the frontal cortex of schizophrenic patients J. Neural Transm. Gen. Sect. 85 1991 19 29
3. F.M. Benes, S.L. Vincent, A. Marie, and Y. Khan Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects Neuroscience 75 1996 1021 1031
4. N.J.M. Birdsall, N.M. Nathanson, and R.D. Schwartz Muscarinic receptors: it's a knockout Trends Pharmacol. Sci. 22 5 2001 215 219
5. 2A receptor mRNAs and binding site densities are differentially altered in schizophrenia Neuropsychopharmacology 15 5 1996 442 455
6. J.R. Bustillo, L.M. Rowland, J. Lauriello, H. Petropoulos, R. Hammond, B. Hart, and W.M. Brooks High choline concentrations in the caudate nucleus in antipsychotic-naïve patients with schizophrenia Am. J. Psychiatry 159 2002 130 133
7. 2A receptor antagonists inhibit potassium-stimulated gamma-aminobutyric acid release in rat frontal cortex Eur. J. Pharmacol. 309 1996 25 31
8. J.M. Crook, E. Tomaskovic-Crook, D.L. Copolov, and B. Dean Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation Biol. Psychiatry 48 2000 381 388
9. J.M. Crook, E. Tomaskovic-Crook, D.L. Copolov, and B. Dean Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Broadmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment Am. J. Psychiatry 158 2001 918 925
10. J.G. Csernansky, R. Mahmoud, and R. Brenner Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia N. Engl. J. Med. 346 2002 16 22
11. B. Dean, J.M. Crook, K. Opeskin, C. Hill, N. Keks, and D.L. Copolov The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia Mol. Psychiatry 1 1996 54 58
12. B. Dean, and W. Hayes Decreased frontal cortical serotonin2A receptors in subjects with schizophrenia Schizophr. Res. 21 1996 133 139
13. B. Dean, T. Hussain, W. Hayes, E. Scarr, S. Kitsoulis, and C. Hill Changes in serotonin2A and GABAA receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex J. Neurochem. 72 4 1999 1593 1599
14. B. Dean A predicted cortical serotonergic/cholinergic/GABAergic interface as a site of pathology in schizophrenia Clin. Exp. Pharmacol. Physiol. 28 2001 74 78
15. T. Fujimoto, T. Nakano, T. Takano, K. Takeuchi, K. Yamada, and T. Fukuzako Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia Biol. Psychiatry 40 1996 14 18
16. T. Hashimoto, N. Kitamura, Y. Kajimoto, Y. Shirai, O. Shirakawa, and T. Mita Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia Psychopharmacology 112 Suppl. 1993 S35 S39
17. C. Hill, S. Roberts, N. Keks, B. Dean, A. MacKinnon, and D. Copolov Diagnostic Instrument for Brain Studies 1996 Mental Health Research Institute Melbourne
18. H. Hirano, J. Day, and H.C. Fibiger Serotonergic regulation of acetylcholine release in rat frontal cortex J. Neurochem. 65 1995 1139 1145
19. J.N. Joyce The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine Psychopharmacology 112 1993 S16 S34
20. J.N. Joyce, A. Shane, N. Lexow, A. Winokur, M.F. Casanova, and J.E. Kleinman Serotonin uptake sites and serotonin resceptors are altered in the limbic system of schizophrenics Neuropsychopharmacology 8 4 1993 315 336
21. H.Y. Meltzer Biological studies in schizophrenia Schizophr. Bull. 13 1987 77 107
22. A. Meyer-Lindenberg, R.S. Miletich, P.D. Kohn, G. Esposito, R.E. Carson, M. Quarantelli, D.R. Weinberger, and K.F. Berman Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia Nat. Neurosci. 5 3 2002 267 270
23. T. Mita, S. Hanada, N. Nishio, T. Kuno, H. Nakai, Y. Yamadori, Y. Mizoi, and C. Tanaka Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics Biol. Psychiatry 21 1986 1407 1414
24. C. Pantelis, T.R.E. Barnes, H.E. Nelson, S. Tanner, L. Weatherley, A.M. Owen, and T.W. Robbins Frontal-striatal cognitive deficits in patients with chronic schizophrenia Brain 120 1997 1823 1843
25. R.E. Powers The Neuropathology of Schizophrenia J. Neuropathol. Exp. Neurol. 58 7 1999 679 690
26. D. Pralong, E. Tomaskovic-Crook, K. Opeskin, D. Copolov, and B. Dean Serotonin2A receptors are reduced in the planum temporale from subjects with schizophrenia Schizophr. Res. 44 2000 35 45
27. T. Shiori, H. Hamanaka, T. Kato, J. Murashita, K. Fujii, and T. Inubushi Proton magnetic resonance spectroscopy of the basal ganglia in patients with schizophrenia: a preliminary report Schizophr. Res. 22 1996 19 26
28. A.J.Q. Trojanowski Recent advances in defining the neuropathology of schizophrenia Acta Neuropathol. 92 1996 217 231
29. J. Volavka, P. Czobor, B. Sheitman, J.P. Lindenmayer, L. Citrome, J.P. McEvoy, T.B. Cooper, M. Chakos, and J.A. Lieberman Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder Am. J. Psychiatry 159 2002 255 262
30. F.X. Vollenweider, M.F.I. Vollenweider-Scherpenhuyzen, A. Babler, H. Vogel, and D. Hell Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action NeuroReport 9 1998 3897 3902
31. F.X. Vollenweider, P. Vontobel, D. Hell, and Leenders KL 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man-a PET study with [C11]raclopride Neuropsychopharmacology 20 5 1999 424 433